However, anti-CD73 Abs in therapies have to be analyzed individually, as for instance the TGF-β-rich tumor milieu confers resistance to anti-4-1BB therapy by sustaining CD73 expression, primarily on infiltrating CD8+ T cells across several tumor models, and making them rather immunosuppressive. Here, TGFB1 is linked to neoplasm.